Teva To Investigate High-Dose Copaxone
This article was originally published in The Pink Sheet Daily
Executive Summary
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.
You may also be interested in...
Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS
Compound fails to meet primary and secondary trial endpoints.
Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS
Compound fails to meet primary and secondary trial endpoints.
Copaxone Sales Will Continue Growth Regardless Of Tysabri Re-Launch, Teva Says
Teva expects sales of its multiple sclerosis therapy Copaxone (glatiramer)to continue to grow in 2006 regardless of whether FDA allows the re-launch of competitor Tysabri (natalizumab)